Yuanrong Biotechnology Launches Series B Funding Round, Eyes Independent Listing

Yuanrong Biotechnology has recently announced the commencement of its Series B funding round and is actively preparing for an independent listing. This development follows the company's successful completion of a 410 million yuan Series A funding round in 2022. The Series B funding round is part of Yuanrong Biotechnology's broader strategy to strengthen its financial position and expand its market reach.

Yuanrong Biotechnology, founded by Qu Jinguo, is a leading player in the field of advanced cell biology automation and low-temperature storage equipment. The company's mission is to address critical pain points in the biopharmaceutical industry, particularly in the area of biological sample storage. With a comprehensive product portfolio, Yuanrong Biotechnology offers innovative solutions tailored to various storage needs and application scenarios, ensuring full liquid nitrogen cold chain protection, unmanned sample storage, and 5G-IoT remote management.

As of December 2024, Yuanrong Biotechnology has accumulated over 600 patent applications worldwide, with more than 500 patents granted. The company's Orcella Instruments brand, specifically the Orcella duo1100S fully automated ultra-low temperature storage system, received the "2025 Outstanding New Product Award" at the International Society for Biological and Environmental Repositories (ISBER) awards ceremony in Canada. This recognition highlights the system's technological innovation, industry impact, data support, and market demand.

In March 2025, Yuanrong Biotechnology was selected for the National High-Quality Medical Device Export Selection Guide (2025), further solidifying its position as a leader in the biotechnology sector. The company's strategic initiatives, including the Series B funding round and preparations for an independent listing, reflect its commitment to driving innovation and growth in the biotechnology industry.